Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections

Inclusion Criteria:

* Adult (≥ 18 years)
* Hospitalized patient with clinically significant monomicrobial UTI
* Complicated UTI due to ESBL producing enterobacteriaceae (pyelonephritis, prostatitis or renal abscess) requiring parenteral antimicrobial therapy
* Susceptibility to temocillin and carbapenem as evidenced by testing results
* For woman able to procreate: negative pregnancy test and use of an effective method of contraception (abstinence, oral contraceptives, intra-uterine device, diaphragm with spermicide and condom). All forms of hormonal contraception are acceptable
* Signed informed consent by patient himself (able or under curatorship) or his legal representative (patient unable to give his consent or under tutorship)
* Patient affiliated to the social security system

Exclusion Criteria:

* Patient infected with a bacteria which is not an ESBL-producing enterobacteriaceae.
* Polymicrobial infection.
* Hypersensitivity and/or previous intolerance to carbapenem or temocillin, or penicillins or any other beta-lactam.
* Patient with a contraindication to any of the drugs to be used in research
* Patient presenting another site of infection than urinary (except onset of bacteraemia from urinary tract origin due to Gram negative bacteria).
* Woman who is pregnant, breastfeeding, or expecting to conceive at any time during the study (pregnancy test will be conducted for woman without menopause).
* Palliative care of life expectancy \< 90 days.
* Ongoing empirical treatment of the urinary tract infections with carbapenem or temocillin \> 24 hours before randomization
* Delay in randomization \> 48 hours after identification of ESBL producing enterobacteriaceae in urinary and/or blood culture.
* Participation in other clinical trial for the infection.